drugset
Drugs / E/C/F/TAF
last change Jul 2017 re-read 9 days ago

E/C/F/TAF

also known as elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 3 NCT01967940 Background Oct 2013 → May 2015 AIDS Gilead Sciences Completed Met primary

Press releases naming this drug 1 release

DateIssuerRelease
2015-07-21 Gilead Sciences Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF) gilead.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as E/C/F/TAF ClinicalTrials.gov intervention name — accepted as the source's own label NCT01967940 ↗
Known as elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide “Following the washout period, all participants who received TAF in Part 1 and have a \> 0.5 log10 decline in HIV-1 RNA will receive...” NCT01967940 ↗
Route Oral “150/150/200/10 mg STR administered orally once daily with food” NCT01967940 ↗